China First Domestic COVID-19 Antibody Therapy Moves Towards Green Light
Strong Overseas Efficacy Data
Brii’s antibody combo therapy nears approval in China, based on data from a late-stage study conducted outside the country.
You may also be interested in...
China Touts First COVID Antibody Approval But Border Opening Eludes
The first antibody approval for COVID-19 in China comes amid variant threats and a continued strict Zero COVID policy.
Coronavirus Update: Brii Files US EUA For Antibody Combo
Chinese venture Brii seeks US emergency authorization for its antibody combo, as Chugai aims for wider use of its antibody cocktail in Japan and two other Chinese firms link up on an oral antiviral.
Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage
Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. In this case study, Scrip takes a deep dive into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations.